TOP TIERMARKET NEWSWIRE
News & sentiment

INHIBIKASE THERAPEUT Equity (IKT) — News & AI sentiment

INHIBIKASE THERAPEUT Equity (IKT) news roundup. 5 stories aggregated over the last 30 days. Average 30-day sentiment is 53/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
5
avg sentiment 53/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
0
0 buys · 0 sells

IKT news in the last 24 hours, 7 days, 30 days and 90 days

How much IKT coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowIKT storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days0—no coverage
Last 30 days553/100IKT headlines →
Last 90 days1651.8/100IKT headlines →

Latest stories on IKT

Nov 10
Nov 10
Nov 10
Nov 10
Oct 27
Oct 20
Oct 20
Oct 20
Oct 20
Oct 20
Oct 13
Chardan initiates Inhibikase Therapeutics stock with neutral rating
Investing.com Analyst Ratings50 · neutralanalyst
Oct 13
Oct 2
Oct 2
Sep 8
Aug 26
Inhibikase Therapeutics GAAP EPS of -$0.11 in-line
Seeking Alpha52 · neutralearnings
Aug 11
Aug 11
Aug 11
Aug 11
Aug 11
Jul 29
Jul 23
Jul 23
Jul 14
Open IKT in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →